✦ LIBER ✦

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer

✍ Scribed by M. Venturini; L. Del Mastro; Franco Testore; Marco Danova; Ornella Garrone; Claudio Lanfranco; Fabio Latini; Mario R. Sertoli; Rita Lionetto; Paola Queirolo; Andrea Ardizzoni; Riccardo Rosso

Publisher: Springer
Year: 1996
Tongue: English
Weight: 160 KB
Volume: 38
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050516

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I dose escalation of combination

A Phase I dose escalation of combination chemotherapy with granulocyte-macrophage–colony stimulating factor in patients with neuroblastoma

✍ M. Carmen Fernandez; Mark D. Krailo; Robert R. Gerbing; Katherine K. Matthay 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

Mitoxantrone plus vinorelbine with granu

Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study

✍ G. Frasci; G. Comella; P. Comella; F. Salzano; L. Cremone; N. Della Volpe; A. Im 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 781 KB

Phase I / II trial of human recombinant

Phase I / II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer

✍ G. T. Budd; J. Atiba; R. T. Silver; G. Palmer; S. Armstrong; K. Otto; C. Presant 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 96 KB

Beneficial impact of peripheral blood pr

Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor a randomized trial

✍ Alan Kritz; John P. Crown; Robert J. Motzer; Lilian M. Reich; Glenn Heller; Mich 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 672 KB

Dose escalation study of carboplatin wit

Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west Japan

✍ Nobuyuki Katakami; Minoru Takada; Shunichi Negoro; Katsuyasu Ota; Jiro Fujita; K 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 738 KB

## BACKGROUND. We performed a Phase 1-11 trial to determine the maximum tolerated dose of carboplatin (CBDCA) with a fixed dose of VP-16 and granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients. ## METHODS. Treatment consisted of a starting dose of CBDCA, 400

A phase I/II study of high-dose cyclopho

A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies

✍ A. M. Hussein; William P. Petros; Maureen Ross; James J. Vredenburgh; Mary Lou A 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 300 KB